Role of selective V2-receptor-antagonism in septic shock: a randomized, controlled, experimental study

Rehberg, Sebastian; Ertmer, Christian; Lange, Matthias; Morelli, Andrea; Whorton, Elbert; Dünser, Martin; Strohhäcker, Anne-Katrin; Lipke, Erik; Kampmeier, Tim G; Van Aken, Hugo; Traber, Daniel L; Westphal, Martin

doi:10.1186/cc9320

Critical Care

Table 1 Cardiopulmonary variables and mesenteric blood flow

From: Role of selective V₂-receptor-antagonism in septic shock: a randomized, controlled, experimental study

Variable	Group	Baseline	Shock time	4 hours	8 hours	10 hours
HR, beats per min	Placebo	96 ± 2	103 ± 4	123 ± 7^a	115 ± 7	102 ± 5
	AVP	93 ± 2	101 ± 5	112 ± 6	99 ± 5^b	100 ± 2
	V₂ antagonist	95 ± 4	102 ± 3	112 ± 6^a	115 ± 3^a,c	101 ± 2
CI, L/min per m²	Placebo	5.5 ± 0.3	5.8 ± 0.5	8.6 ± 0.8^a	7.9 ± 0.5^a	5.8 ± 0.6
	AVP	5.2 ± 0.3	6.5 ± 0.4	8.5 ± 0.9	6.4 ± 0.8	5.4 ± 0.8
	V₂ antagonist	5.3 ± 0.2	5.9 ± 0.3	9.7 ± 0.5^a	8.2 ± 0.5^a	7.1 ± 0.4
SVRI, dyne·s/cm⁵ per m²	Placebo	1,285 ± 109	758 ± 52^d	636 ± 60	463 ± 38^a	457 ± 107^a
	AVP	1,427 ± 101	664 ± 47^d	596 ± 109	498 ± 84	479 ± 97^a
	V₂ antagonist	1,406 ± 25	714 ± 46^d	509 ± 76^a	388 ± 54^a	464 ± 75^a
MAP, mm Hg	Placebo	91 ± 4	58 ± 4^d	66 ± 3^a	55 ± 3	44 ± 3^a
	AVP	93 ± 2	57 ± 1^d	68 ± 2^a	56 ± 4	43 ± 1^a
	V₂ antagonist	96 ± 2	58 ± 1^d	68 ± 3^a	54 ± 2	51 ± 3^a
SVI, mL/m²	Placebo	59 ± 4	58 ± 7	78 ± 3^a	68 ± 3	55 ± 7
	AVP	56 ± 3	64 ± 2	80 ± 7	63 ± 7	55 ± 9
	V₂ antagonist	53 ± 2	57 ± 3	78 ± 7^a	71 ± 5	70 ± 3
LVSWI, g/m per m²	Placebo	67 ± 3	41 ± 4^d	64 ± 6^a	43 ± 4	22 ± 4^a
	AVP	67 ± 3	42 ± 2^d	60 ± 3^a	26 ± 2^b	21 ± 4^a
	V₂ antagonist	65 ± 3	37 ± 2^d	65 ± 5^a	36 ± 1^c	29 ± 2^c
MPAP, mm Hg	Placebo	14 ± 1	20 ± 1^d	22 ± 1	24 ± 2^a	26 ± 2^a
	AVP	15 ± 0	18 ± 1^d	22 ± 1^a	25 ± 1^a	27 ± 2^a
	V₂ antagonist	15 ± 1	21 ± 1^d	25 ± 2^a	27 ± 1^a	29 ± 1^a
PVRI, dyne·s/cm⁵ per m²	Placebo	106 ± 8	139 ± 22	119 ± 15	119 ± 12	144 ± 30
	AVP	124 ± 9	143 ± 8	90 ± 13^a	81 ± 16^a	150 ± 29
	V₂ antagonist	129 ± 9	150 ± 9	121 ± 26	103 ± 8^a	123 ± 10
Qma, % of baseline	Placebo	100 ± 0	109 ± 17	135 ± 27	94 ± 17	60 ± 10^a
	AVP	100 ± 0	95 ± 7	118 ± 21	86 ± 16	41 ± 8^a
	V₂ antagonist	100 ± 0	95 ± 11	115 ± 11	75 ± 6	43 ± 8^a

^aP < 0.05 versus shock time; ^bP < 0.05 versus placebo; ^cP < 0.05 versus arginine vasopressin (AVP); ^dP < 0.05 versus baseline; each group n = 7. CI, cardiac index; HR, heart rate; LVSWI, left ventricular stroke work index; MAP, mean arterial pressure; MPAP, mean pulmonary arterial pressure; PVRI, pulmonary vascular resistance index; Qma, mesenteric arterial blood flow; SVI, stroke volume index; SVRI, systemic.

Back to article page

ISSN: 1364-8535

Contact us

Submission enquiries: journalsubmissions@springernature.com